ALVAL.PA

Valbiotis SA [ALVAL.PA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALVAL.PA Stock Summary

Top 10 Correlated ETFs

ALVAL.PA

Top 10 Correlated Stocks

ALVAL.PA

In the News

ALVAL.PA Financial details

Company Rating
-
Market Cap
62.32M
Income
-19.45M
Revenue
5.18M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
48
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-4.03
Forward P/E
-
PEG
-0.4
P/S
28.93
P/B
3.72
P/C
-
P/FCF
-8.17
Quick Ratio
2.57
Current Ratio
3
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.91
EPS next Y
-
EPS next Q
-
EPS this Y
28.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.56%
Revenue last 5Y
58.29%
Revenue Q/Q
2727.33%
EPS Q/Q
-76.81%
-
-
-
-
SMA20
-8.26%
SMA50
-25.37%
SMA100
-21.88%
Inst Own
-
Inst Trans
-
ROA
-45%
ROE
-89%
ROC
-0.63%
Gross Margin
79%
Oper. Margin
-449%
Profit Margin
-460%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.82-7.5
52W High
-85.71%
52W Low
-50%
RSI
40.8
Rel Volume
0.27
Avg Volume
33.43K
Volume
8.87K
Perf Week
-2.91%
Perf Month
-9.91%
Perf Quarter
-19.35%
Perf Half Y
-23.66%
-
-
-
-
Beta
-0.299
-
-
Volatility
0.01%, 0.04%
Prev Close
0%
Price
1
Change
0%

Something similar

Top by Market Cap
META
MSF.DE
DHR-PB
AMZ.DE
AAPL
Top Correlated ETFs
XSHC.L
IHCU.L
XLVP.L
DSB.PA
ESGB.TO
Top Correlated Stocks
OXUR.BR
IQE.L
OVB.L
PEBB.L
PIA.MI
Similar Market Cap
SEAIX
M9SA.DE
TDSE
DBX8.DE
6193.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 33.43K
  • Market Capitalization 62.32M
  • Employee 48
  • CEO Mr. Sebastien Peltier HDR, Ph.D.
  • Headquarters Périgny,FR
  • IPO Date 2017-06-07
  • Website https://www.valbiotis.com

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.